| Market Capitalization (Millions $) |
74 |
| Shares
Outstanding (Millions) |
11 |
| Employees |
54 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-40 |
| Cash Flow (TTM) (Millions $) |
3 |
| Capital Exp. (TTM) (Millions $) |
0 |
Corbus Pharmaceuticals Holdings Inc
Corbus Pharmaceuticals Holdings Inc. is a clinical-stage biopharmaceutical company that is focused on discovering, developing, and commercializing innovative therapies to address serious and unmet medical needs in the areas of inflammation and fibrosis. The company is headquartered in Norwood, Massachusetts, and was founded in 2009.
Corbus Pharmaceuticalse lead product candidate is lenabasum, which is a first-in-class, oral, small molecule drug that acts as a selective cannabinoid receptor type 2 (CB2) agonist. Lenabasum has been designed to target and activate CB2 receptors on immune cells, resolving chronic inflammation and fibrosis without impairing normal immune function.
The company has several clinical trials underway for lenabasum, including a phase 3 study in systemic sclerosis, a phase 2b study in dermatomyositis, and a phase 2 study in cystic fibrosis. In addition to these trials, Corbus is also exploring the potential for lenabasum in other indications, such as lupus, systemic lupus erythematosus, and COVID-19.
Beyond lenabasum, Corbus Pharmaceuticals has a pipeline of drug candidates in various stages of development. This includes CRB-4001, a cannabinoid receptor type 1 (CB1) inverse agonist that is in preclinical development for the treatment of nonalcoholic steatohepatitis (NASH), and CRB-5003, a peripherally restricted CB1 inverse agonist that is being developed for the treatment of chronic pain and other indications.
Corbus Pharmaceuticals has a strong focus on patient advocacy and building relationships with patient communities. The company has established partnerships with patient organizations to raise awareness about the diseases it is targeting and to provide educational resources to patients and caregivers.
Corbus Pharmaceuticals is led by a team of experienced industry professionals, including Chief Executive Officer Yuval Cohen, who has more than 30 years of experience in the biopharmaceutical industry, and Chief Medical Officer Barbara White, who has extensive experience in clinical development and regulatory affairs. The company has also assembled a world-class scientific advisory board that includes leading experts in the fields of inflammation and fibrosis.
Overall, Corbus Pharmaceuticals is a company that is dedicated to developing innovative therapies that can make a significant difference in the lives of patients suffering from serious and debilitating diseases. The companyes focus on patient advocacy and strong leadership team positions it well for long-term success in the biopharmaceutical industry.
Company Address: 500 River Ridge Drive Norwood 2062 MA
Company Phone Number: 963-0100 Stock Exchange / Ticker: NASDAQ CRBP
|
11.32%